AR026974A1 - N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen - Google Patents

N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen

Info

Publication number
AR026974A1
AR026974A1 ARP000106680A ARP000106680A AR026974A1 AR 026974 A1 AR026974 A1 AR 026974A1 AR P000106680 A ARP000106680 A AR P000106680A AR P000106680 A ARP000106680 A AR P000106680A AR 026974 A1 AR026974 A1 AR 026974A1
Authority
AR
Argentina
Prior art keywords
useful
inhibitors
pharmaceutical compositions
compositions containing
oxazolil
Prior art date
Application number
ARP000106680A
Other languages
English (en)
Spanish (es)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/464,511 external-priority patent/US6262096B1/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR026974A1 publication Critical patent/AR026974A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP000106680A 1999-12-15 2000-12-15 N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen AR026974A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/464,511 US6262096B1 (en) 1997-11-12 1999-12-15 Aminothiazole inhibitors of cyclin dependent kinases
US61662700A 2000-07-26 2000-07-26

Publications (1)

Publication Number Publication Date
AR026974A1 true AR026974A1 (es) 2003-03-05

Family

ID=27041008

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106680A AR026974A1 (es) 1999-12-15 2000-12-15 N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen

Country Status (29)

Country Link
EP (1) EP1240166B1 (https=)
JP (1) JP2003516987A (https=)
KR (1) KR100738132B1 (https=)
CN (1) CN1433416A (https=)
AR (1) AR026974A1 (https=)
AT (1) ATE289306T1 (https=)
AU (1) AU783719B2 (https=)
BR (1) BR0016424A (https=)
CA (1) CA2394552A1 (https=)
CO (1) CO5261565A1 (https=)
CZ (1) CZ20022015A3 (https=)
DE (1) DE60018205T2 (https=)
DK (1) DK1240166T3 (https=)
EG (1) EG24168A (https=)
ES (1) ES2236034T3 (https=)
HK (1) HK1049661B (https=)
HU (1) HUP0301032A3 (https=)
IL (2) IL149755A0 (https=)
MX (1) MXPA02005870A (https=)
MY (1) MY125768A (https=)
NO (1) NO323726B1 (https=)
NZ (1) NZ519120A (https=)
PE (1) PE20011026A1 (https=)
PL (1) PL364921A1 (https=)
PT (1) PT1240166E (https=)
RU (1) RU2002119016A (https=)
TW (1) TWI273103B (https=)
UY (1) UY26481A1 (https=)
WO (1) WO2001044242A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
CA2417254A1 (en) * 2000-07-26 2002-02-07 Bristol Myers Squibb Company N-¢5-¢¢¢5-alkyl-2-oxazolyl!methyl!thio!-2-thiazolyl! carboxamide inhibitors of cyclin dependent kinases
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
US7392929B1 (en) 2004-07-26 2008-07-01 Zephyros, Inc. Weldable synthetic material
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
MX2008005814A (es) 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8236128B2 (en) 2006-10-26 2012-08-07 Zephyros, Inc. Adhesive materials, adhesive parts formed therewith and their uses
US20110294782A1 (en) * 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016319125B2 (en) * 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
KR100738132B1 (ko) 2007-07-10
KR20020067546A (ko) 2002-08-22
PL364921A1 (en) 2004-12-27
RU2002119016A (ru) 2004-01-10
EG24168A (en) 2008-09-10
HK1049661A1 (en) 2003-05-23
ES2236034T3 (es) 2005-07-16
CN1433416A (zh) 2003-07-30
EP1240166B1 (en) 2005-02-16
NO323726B1 (no) 2007-07-02
HUP0301032A3 (en) 2009-03-30
AU783719B2 (en) 2005-12-01
WO2001044242A9 (en) 2001-11-08
DE60018205T2 (de) 2006-02-16
CO5261565A1 (es) 2003-03-31
IL149755A (en) 2009-09-22
DK1240166T3 (da) 2005-06-20
CA2394552A1 (en) 2001-06-21
PT1240166E (pt) 2005-07-29
EP1240166A1 (en) 2002-09-18
HUP0301032A2 (hu) 2003-08-28
MXPA02005870A (es) 2003-01-28
DE60018205D1 (en) 2005-03-24
PE20011026A1 (es) 2001-12-02
CZ20022015A3 (cs) 2003-02-12
UY26481A1 (es) 2001-07-31
MY125768A (en) 2006-08-30
HK1049661B (en) 2005-10-07
JP2003516987A (ja) 2003-05-20
IL149755A0 (en) 2002-12-01
NZ519120A (en) 2004-03-26
NO20022817D0 (no) 2002-06-13
NO20022817L (no) 2002-08-14
ATE289306T1 (de) 2005-03-15
TWI273103B (en) 2007-02-11
AU2726401A (en) 2001-06-25
BR0016424A (pt) 2002-08-20
WO2001044242A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
AR026974A1 (es) N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen
AR030563A1 (es) N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]carboxamidas inhibidoras de cinasas dependientes de la ciclina y composiciones farmaceuticas que las contienen
UY26480A1 (es) Inhibidores de n - (5 - ( 5 - alquil - 2 - oxazolil) metil ) tio) - 2 - tiazolil) - carboxamida de cinasas dependientes de ciclina
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
AR035374A1 (es) Un derivado de fenilacetamido-pirazol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un kit que comprende dicho derivado o composicion, un metodo para tratar desordenes proliferativos celularaes asociados con una actividad quinasa dependiente de ciclo c
EA200001171A1 (ru) Бициклические пиримидины и бициклические 3,4-дигидропиримидины как ингибиторы клеточной пролиферации
AR017852A1 (es) COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER.
AP1853A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents.
UY27592A1 (es) Nuevo uso
AR040580A1 (es) Derivados de pirazol heterobiciclico como inhibidores de la quinasa
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
EA200400283A1 (ru) Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
BRPI0414111A (pt) inibidores heterocìclicos de mek e métodos de uso dos mesmos
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DK0649418T3 (da) 7-(2-aminoethyl)benzothiazolon
DK0647219T3 (da) Derivater i vitamin D-serien modificeret i 20-positionen, fremgangsmåde til fremstilling af sådanne derivater, mellemprodukter itl brug ved fremgangsmåde, farmaceutiske præparater indeholdende derivaterne samt deres anvendelse ved fremstilling af lægemidler
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
PT652874E (pt) 2-heterociclico-5-hidroxi-1,3-pirimidinas uteis como agentes anti-inflamatorios
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
DE69612540D1 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von Krankheiten in Zusammenhang mit aktivem Sauestoff und freien Radikalen

Legal Events

Date Code Title Description
FB Suspension of granting procedure